Latest News in the pharma Industry

Research & Development

MicroJect Reactor technology to take centre stage in new partnership

MicroJect Reactor technology to take centre stage in new partnership

16 Jan 2017

leon nanodrugs' MJR technology offers reformulation options that address API solubility issues.

Read more 
A-Skin secures patent for groundbreaking skin engineering therapy

A-Skin secures patent for groundbreaking skin engineering therapy

16 Jan 2017

WHF therapy can be directly applied on a wound to stimulate the natural human wound healing process.

Read more 
Merck Licenses four oncology R&D programs from Vertex

Merck Licenses four oncology R&D programs from Vertex

12 Jan 2017

All programs (two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs) have first-in-class and best-in-class potential.

Read more 
FDA grants Fast-Track Designation to RHB-104 for nontuberculous mycobacteria infections

FDA grants Fast-Track Designation to RHB-104 for nontuberculous mycobacteria infections

12 Jan 2017

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation.

Read more 
Lilly and Merck expand immuno-oncology collaboration

Lilly and Merck expand immuno-oncology collaboration

11 Jan 2017

New study to evaluate combination of Lartruvo and Keytruda.

Read more 
Takeda and PvP Biologics sign development agreement around novel therapeutic for celiac disease

Takeda and PvP Biologics sign development agreement around novel therapeutic for celiac disease

9 Jan 2017

KumaMax could provide hope celiac patients who try, but are unable to completely avoid gluten exposure in their diets,

Read more 
Catalent to develop softgel capsules for JOT's leading orphan disease candidates

Catalent to develop softgel capsules for JOT's leading orphan disease candidates

9 Jan 2017

JOTROL is being developed to remedy resveratrol’s poor bioavailability and dose limiting gastrointestinal side effects.

Read more 
BMS and Janssen to collaborate to evaluate Opdivo in combination with Darzalex

BMS and Janssen to collaborate to evaluate Opdivo in combination with Darzalex

5 Jan 2017

Phase Ib/II studies to explore a novel immuno-oncology combination in hematological and solid tumours with high unmet medical need.

Read more 
Noxxon Pharma licenses and assigns preclinical  Spiegelmer programs to Aptarion

Noxxon Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion

5 Jan 2017

Noxxon continues transition to clinical oncology company.

Read more 
Xigen’s innovative JNK inhibitor, Brimapitide, delivers positive Phase II results in inflammatory eye disease

Xigen’s innovative JNK inhibitor, Brimapitide, delivers positive Phase II results in inflammatory eye disease

5 Jan 2017

The company's long-acting therapeutic peptides are designed to allow the efficient delivery of the active element to intracellular targets.

Read more 
Corbus Pharmaceuticals completes Phase II study of JBT-101 for the treatment of cystic fibrosis

Corbus Pharmaceuticals completes Phase II study of JBT-101 for the treatment of cystic fibrosis

1 Jan 2017

Resunab is designed to resolve inflammation thus having the potential to provide significant clinical benefit to CF patients, importantly without immunosuppression.

Read more 
PharmaCyte Biotech’s cannabinoid therapy may offer potential for childhood brain cancers

PharmaCyte Biotech’s cannabinoid therapy may offer potential for childhood brain cancers

1 Jan 2017

Reported research continues to demonstrate the anti-cancer properties of cannabinoids.

Read more